Metformin induces a senescence-associated gene signature in breast cancer cells

Journal of Health Care for the Poor and Underserved

Volumn 24, Issue SUPPL1, 2013, Pages 93-103

  Williams, Christopher C ^a   Singleton, Brittany A ^a   Llopis, Shawn D ^a   Skripnikova, Elena V ^a  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

Breast cancer; DDIT3; ER stress; GDF15; Metformin; PTGS1

Indexed keywords

METFORMIN;

ARTICLE; BREAST TUMOR; CELL AGING; CULTURE TECHNIQUE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN;

BREAST NEOPLASMS; CELL AGING; CELL CULTURE TECHNIQUES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METFORMIN;

EID: 84873672072     PISSN: 10492089     EISSN: 15486869     Source Type: Journal    
DOI: 10.1353/hpu.2013.0044     Document Type: Article

References (23)

1. Walker B, Figgs LW, Zahm SH. Diferences in cancer incidence, mortality, and survival between African Americans and whites. Environ Health Perspect. 1995 Nov;103 (Suppl 8): 275-281.
2. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative-breast cancer. Clin Breast Cancer. 2009 Jun;(9 Suppl 2): S73-S81.
3. Morris SR, Carey LA. 2007. Molecular profiling in breast cancer. Rev Endocr Metab Disord. 2007 Sep; 8(3):185-198.
4. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295(2):2492-2502.
5. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008 May;109(1): 123-139.
6. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010 Nov; 3(11):1451-1461.
7. Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009 Jul;8(13):2031-2040.
8. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, et al. Metformin against TGFβ- induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fbrosis. Cell Cycle. 2010 Nov; 9(22):4461-4468.
9. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, et al. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 2010 Mar; 9(6): 1057-1064.
10. Ben Sahra I, Regazzetti C, Robert G, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011 Jul; 71(13): 4366-4372.
11. Hede K. Doctors seek to prevent breast cancer recurrence by lowering insulin levels. J Natl Cancer Inst. 2008 Jul;100(8):530-532.
12. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006 Nov; 66(2):10269-10273.
13. Song C W, Lee H, Dings R P, et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012; 2: 362.
14. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, et al. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle. 2010 Sep; 9(18):3807-3814.
15. Bednar F, Simeone DM. Metformin and cancer stem cells: old drug, new targets. Cancer Prev Res (Phila). 2012 Mar; 5(3): 351-354.
16. Cuf S, Corominas-Faja B, Vazquez-Martin A, et al. Metformin-induced preferential killing of breast cancer initiating CD441CD242/low cells is sufficient to overcome primary resistance to trastuzumab in HER21 human breast cancer xenografs. Oncotarget. 2012 Apr; 3(4): 395-398.
17. Deng XS, Wang S, Deng A, et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012 Jan;11(2):367-376.
18. Bayraktar S, Hernadez-Aya LF, Lei X, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2012 Mar; 118(5): 1202-1211.
19. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999 Dec;18(55):7908-7916.
20. Silva AM, Wang D, Komar AA, et al. Salicylates trigger protein synthesis inhibition in a protein kinase R-like endoplasmic reticulum kinase-dependent manner. J Biol Chem. 2007 Apr; 282(14):10164-10171.
21. Baek SJ, Kim KS, Nixon JB, et al. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol. 2001 Apr; 59(4):901-908.
22. Baek SJ, Wilson LC, Lee CH, et al. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ter. 2002 Jun; 301(3):1126-1131.
23. Yang H, Park SH, Choi HJ, et al. Te integrated stress response-associated signals modulates intestinal tumor cell growth by NSAID-activated gene 1 (NAG-1/MIC-1/ PTGF-beta). Carcinogenesis. 2010 Apr;31(4):703-711.